World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
34449
World Ranking
13491
National Ranking
1257

Overview

Paresh Vyas is affiliated with the University of Oxford in the United Kingdom. Their research primarily addresses topics in medicine and biochemistry, genetics, and molecular biology, with a significant focus on hematology, molecular biology, and genetics as subfields.

Their work concentrates on multiple areas within hematologic malignancies and related treatments. Key research topics include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Protein Degradation and Inhibitors
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Histone Deacetylase Inhibitors Research
  • Chronic Lymphocytic Leukemia Research

Paresh Vyas has contributed extensively to peer-reviewed journals. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HemaSphere

Notable recent papers authored by or involving Paresh Vyas are:

  • "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data," published in Blood in 2022
  • "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes," published in New England Journal of Medicine in 2020
  • "SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS," published in Blood in 2020
  • "Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial," published in The Lancet Oncology in 2021
  • "Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia," published in Journal of Clinical Oncology in 2020

Paresh Vyas has collaborated frequently with several researchers, including:

  • David A. Sallman
  • Naval Daver
  • Marlen Metzner
  • Andrew H. Wei
  • Courtney D. DiNardo

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Elli Papaemmanuil;Moritz Gerstung;Luca Malcovati;Sudhir Tauro

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts

    E. Papaemmanuil;M. Cazzola;J. Boultwood;L. Malcovati

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

    Gerrit J. Schuurhuis;Michael Heuser;Sylvie Freeman;Marie Christine Béne

  • Assessment of Minimal Residual Disease in Standard-Risk AML.

    Adam Ivey;Robert Kerrin Hills;Michael A. Simpson;Jelena V. Jovanovic

  • Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

    Max Jan;Thomas M. Snyder;M. Ryan Corces-Zimmerman;Paresh Vyas

  • Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

    Nicolas Goardon;Emanuele Marchi;Ann Atzberger;Lynn Quek

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

    Oliver Goodyear;Angelo Agathanggelou;Igor Novitzky-Basso;Shamyla Siddique

  • Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

    Oliver C. Goodyear;Mike Dennis;Nadira Y. Jilani;Nadira Y. Jilani;Justin Loke

  • Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

    Y S Ju;L B Alexandrov;M Gerstung;I Martincorena

  • Factors influencing success of clinical genome sequencing across a broad spectrum of disorders

    Jenny C. Taylor;Jenny C. Taylor;Hilary C. Martin;Stefano Lise;John Broxholme

  • Consequences of GATA-1 Deficiency in Megakaryocytes and Platelets

    Paresh Vyas;Kenneth Ault;Carl W. Jackson;Stuart H. Orkin

  • Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

    Alice Giustacchini;Supat Thongjuea;Nikolaos Barkas;Petter S Woll

  • THE MODE OF ACTION OF ASPIRIN-LIKE DRUGS : EFFECT ON INDUCIBLE NITRIC OXIDE SYNTHASE

    A R Amin;P Vyas;M Attur;J Leszczynska-Piziak

  • Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo

    Petter S. Woll;Una Kjällquist;Onima Chowdhury;Helen Doolittle

  • Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

    Michael D. Amatangelo;Lynn Quek;Alan Shih;Eytan M. Stein

  • The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase.

    A. R. Amin;P. E. Di Cesare;Pranav Vyas;Mukundan Attur

  • Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia

    Michael Andreeff;Kevin R. Kelly;Karen Yee;Sarit Assouline

Frequent Co-Authors

Charles Craddock
Charles Craddock Queen Elizabeth Hospital Birmingham
Irene Roberts
Irene Roberts University of Oxford
Peter J. Campbell
Peter J. Campbell Wellcome Sanger Institute
Nigel H. Russell
Nigel H. Russell University of Nottingham
Eva Hellström-Lindberg
Eva Hellström-Lindberg Karolinska University Hospital
Mario Cazzola
Mario Cazzola University of Pavia
David Grimwade
David Grimwade King's College London
Anna Schuh
Anna Schuh University of Oxford
Robert Kerrin Hills
Robert Kerrin Hills University of Oxford
Douglas R. Higgs
Douglas R. Higgs University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always require going to medical school. There are a variety of healthcare administration degree options available online. These programs are ideal for those who want to focus on the business side of healthcare, such as managing hospitals or leading healthcare teams.

For nurses seeking to advance their careers, rn to fnp bridge programs offer a flexible way to transition from an Associate Degree in Nursing (ADN) to becoming a Family Nurse Practitioner (FNP). These online pathways allow working professionals to upskill while still supporting patient care.

Nutrition is another crucial field in healthcare. If you’re interested in dietetics or wellness coaching, an online nutritionist degree can open doors to roles in hospitals, clinics, and community organizations.

As you compare programs, accreditation is vital. Learn more about which online healthcare administration programs have cahme accreditation? to ensure your degree meets industry standards and enhances your career prospects.

Best Scientists Citing Paresh Vyas

Trending Scientists

Recently Published Articles